Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus PAROMOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAFAIR versus PAROMOMYCIN SULFATE.
GENTAFAIR vs PAROMOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Paromomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in susceptible bacteria. It also has direct amebicidal activity against Entamoeba histolytica by inhibiting protein synthesis.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
25-35 mg/kg/day orally in 3 divided doses for 5-10 days for intestinal amebiasis; 1 g orally every 8 hours for 7 days for cryptosporidiosis.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Terminal elimination half-life: 2–3 hours in normal renal function; extends to 24–48 hours or longer in severe renal impairment, necessitating dose adjustment.
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted in urine within 24 hours; negligible biliary/fecal elimination.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic